Join us on Wednesday, April 21st, at 6pm CT for an exciting and informative discussion about living with multiple myeloma.
Host and patient advocate James Omel, MD, will talk to Dr. Muhamed Baljevic, MD, FACP, Medical Hematologist Oncologist at Nebraska Medicine and Dr. Madhu Midathada, MD, Medical Oncologist at Nebraska Hematology Oncology, about everything from the latest treatment options to managing side effects. Our experts will cover your questions, ranging from new treatment protocols to the latest vaccine news.
Dinner accommodations will be provided by Patient Power to each night's first 30 registrants in the form of an Amazon gift card that can be used at Whole Foods or Amazon Fresh. Limit one per household.
Send your myeloma-related questions in advance to firstname.lastname@example.org.
Support for this series has been provided by Karyopharm Therapeutics. Patient Power maintains complete editorial control and is solely responsible for program content.
This event is intended for residents of Nebraska, Eastern Colorado, South Dakota, Kansas, Missouri, Wyoming and Iowa. We welcome everyone outside the region to watch the webinar on FACEBOOK LIVE on Wednesday, 4/21 at 6pm CT. See you soon!
Hosts and Guests
James Omel MD
Muhamed Baljevic MD, FACP
Medical Hematologist Oncologist, Nebraska Medicine
Madhu V. Midathada MD
Medical Oncologist, Nebraska Hematology Oncology
Already have an account? Login and register
Monday, April 19, 2021
Join us on Monday, April 19th, at 6pm CT for an exciting and informative discussion about living with multiple myeloma.
Tuesday, April 20, 2021
Hello North Carolina! Join us on Tuesday, April 20th, at 6pm EST for an exciting and informative discussion around living with multiple myeloma, hosted in partnership with the Atrium Health Levine Cancer Institute.
Wednesday, April 21, 2021
Join us for a live program on Wednesday, April 21st at 2pm EST as Esther Schorr, Patient Power co-founder and care partner, and Michele Nadeem-Baker, patient advocate and CLL survivor, discuss the latest breakthroughs in CLL treatment, clinical trials and combination therapies.